Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, HV Amsterdam, The Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Paediatric Gastroenterology, Amsterdam Gastroenterology Endocrinology Metabolism, De Boelelaan, Amsterdam, Netherlands.
J Crohns Colitis. 2022 Nov 23;16(11):1777-1790. doi: 10.1093/ecco-jcc/jjac079.
Paediatric inflammatory bowel disease [IBD] is characterized by altered immunological and metabolic pathways. Metabolomics may therefore increase pathophysiological understanding and could develop into characterization of biomarkers for diagnosis and IBD treatment response. However, no uniform metabolomic profiles have been identified to date. This systematic review aimed to identify faecal metabolomic signatures in paediatric IBD vs controls, and to describe metabolites associated with disease activity and treatment response.
A literature search was performed in Embase, Medline, Web of Science and Cochrane Library. Studies assessing faecal metabolomics in paediatric patients < 18 years with IBD [de novo, active, inactive] with comparative groups [IBD vs non-IBD; responders vs non-responders] were included. The quality of included studies was assessed according to the Newcastle-Ottawa Scale.
Nineteen studies were included [540 patients with IBD, 386 controls], assessing faecal short-chain fatty acids [SCFA] [five studies], amino acids [AA] [ten studies], bile acids [BA] [eight studies] and other metabolites [nine studies] using various methodologies. Significantly increased levels of AA [particularly phenylalanine], primary BA and lower levels of secondary BA were described in paediatric IBD compared to controls. Faecal SCFA results varied across studies. Additionally, responders and non-responders to exclusive enteral nutrition and infliximab showed differences in baseline faecal metabolites [based on BA, AA].
This systematic review provides evidence for distinct faecal metabolomic profiles in paediatric IBD. However, results varied across studies, possibly due to differences in study design and applied analytical techniques. Faecal metabolomics could provide more insight into host-microbial interactions in IBD, but further studies with standardized methodologies and reporting are needed.
小儿炎症性肠病(IBD)的特点是免疫和代谢途径改变。代谢组学因此可能增加对病理生理学的理解,并可能发展为用于诊断和 IBD 治疗反应的生物标志物特征描述。然而,迄今为止尚未确定统一的代谢组学特征。本系统评价旨在确定小儿 IBD 与对照相比粪便代谢组学特征,并描述与疾病活动和治疗反应相关的代谢物。
在 Embase、Medline、Web of Science 和 Cochrane Library 中进行文献检索。纳入评估小儿 IBD[初发、活动、缓解]患者粪便代谢组学的研究,比较组为[IBD 与非 IBD;应答者与非应答者],并纳入研究。根据纽卡斯尔-渥太华量表评估纳入研究的质量。
纳入了 19 项研究[540 例 IBD 患者,386 例对照],评估粪便短链脂肪酸(SCFA)[5 项研究]、氨基酸(AA)[10 项研究]、胆汁酸(BA)[8 项研究]和其他代谢物[9 项研究],采用了多种方法。与对照相比,小儿 IBD 中 AA[特别是苯丙氨酸]、初级 BA 水平升高,次级 BA 水平降低。粪便 SCFA 结果在不同研究中存在差异。此外,接受肠内营养和英夫利昔单抗的应答者和非应答者在基线粪便代谢物[基于 BA、AA]上存在差异。
本系统评价为小儿 IBD 存在独特的粪便代谢组学特征提供了证据。然而,由于研究设计和应用的分析技术不同,结果在不同的研究中存在差异。粪便代谢组学可以提供更多关于 IBD 中宿主-微生物相互作用的信息,但需要进一步进行具有标准化方法和报告的研究。